AZD-2389

N/A

Report date: 2025/05/27 16:58:43

Base Information

Drug NameAZD-2389
Drug Alias NameAZD2389AZD-2389
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsLiver CirrhosisHepatic InsufficiencyLiver Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenPuerto Rico +[4
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsLiver CirrhosisHepatic InsufficiencyLiver Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A